• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vertex Pharmaceuticals (NQ: VRTX )

    472.80 +1.68 (+0.36%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Vertex Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    47 48 Next >
    Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
    Vertex Pharmaceuticals beat third-quarter expectations on Monday. The company also raised its sales outlook. 
    Via Investor's Business Daily
    Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
    A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
    Via Talk Markets
    Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?
    The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of Election Day on Tuesday. 
    Via Benzinga
    Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts?
    VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock faces bearish trend. 
    Via Benzinga
    Looking Into Vertex Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Market Whales and Their Recent Bets on VRTX Options
    Via Benzinga
    What Analysts Are Saying About Vertex Pharmaceuticals Stock
    Via Benzinga
    Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
    It won't be able to be profitable without hitting its targets for both of these figures. 
    Via The Motley Fool
    As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
    Amid the election, and a Fed rate vote, earnings season roars ahead. 
    Via Investor's Business Daily
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'
    Mad Money's Jim Cramer recommends buying T. Rowe Price Group. "I think it's such a great company," he added. 
    Via Benzinga
    Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years
    Via Benzinga
    These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?
    A look back at the top 10 S&P 500 performing stocks in 2017 under Donald Trump's first year as president and what it could mean for his re-election efforts. 
    Via Benzinga
    Topics Government Stocks
    Exposures Political US Equities
    If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
    Via Benzinga
    12 High-Growth Stocks That Could Deliver Parabolic Returns
    These 12 innovative companies could deliver exponential returns over the next quarter century. 
    Via The Motley Fool
    The Smartest Growth Stock to Buy With $500 Right Now
    This stock might not be available for under $500 for long. 
    Via The Motley Fool
    Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
    Its latest report of clinical data suggests it has a winner on its hands. 
    Via The Motley Fool
    Why We Buy Stocks
    Is fear of missing out (FOMO) controlling your portfolio? 
    Via The Motley Fool
    Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030
    There's no need to change a winning formula. 
    Via The Motley Fool
    Topics Stocks
    Exposures US Equities
    Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)
    Via Benzinga
    Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
    Via Benzinga
    Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever
    These profitable companies are facing long-term growth runways. 
    Via The Motley Fool
    3 No-Brainer Growth Stocks to Buy in October
    These stocks look like slam-dunk picks for growth investors. 
    Via The Motley Fool
    Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
    The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
    Via Benzinga
    2 Biotech Stocks to Buy Hand Over Fist in October
    These longtime leading biotech stocks still have plenty of upside ahead. 
    Via The Motley Fool
    Cathie Wood's Ark Invest Trades: Bets $14M On Amazon Shares — Dumps Robinhood Stock Worth $36M, Embraces Coinbase And Meta
    Cathie Wood's Ark Invest made significant trades in Amazon.com Inc (NASDAQ: AMZN), Robinhood Markets Inc (NASDAQ: HOOD), and Coinbase Global Inc (NASDAQ: COIN) on Tuesday Oct 8, 2024. 
    Via Benzinga
    S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
    Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors. 
    Via Benzinga
    Topics Artificial Intelligence Stocks
    Exposures Artificial Intelligence US Equities
    Insider Trades: How To Find The Top Stocks
    There are dozens of insider trades going on every week. Here are 5 insider stock buys that stand out. 
    Via Talk Markets
    3 Top Stocks That Could Still Rocket Higher in 2024
    Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
    Via The Motley Fool
    2 Superior Growth Stocks That Are Screaming Buys Right Now
    These companies have plenty of growth runway left. 
    Via The Motley Fool
    Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
    Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    47 48 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.